The difference between ranibizumab and aflibercept

Aflibercept (Ziv-aflibercept) and ranibizumab are both vascular endothelial growth factor (VEGF)-targeted drugs. They play an important role in the treatment of various malignant tumors, especially in the treatment of diseases such as colorectal cancer. Although they both target VEGF, there are some differences in their mechanism of action and frequency of dosing. Aflibercept is a unique polyclonal antibody preparation, which is characterized by the fusion of multiple subtypes of humanized monoclonal antibodies, which allows it to broadly neutralize multiple types of VEGF molecules, thereby more comprehensively inhibiting tumor angiogenesis. In contrast, ranibizumab is a more specific humanized monoclonal antibody that mainly targets and neutralizes a specific VEGF receptor, so its scope of action is relatively narrow.